The effect of atorvastatin therapy on skeletal muscle function in hyperlipidemia patients in khartoum
1 Department of Clinical Chemistry, Faculty of Medical Laboratory Sciences, University of Al Zaeim Al Azhari, Khartoum, Sudan.
2 College of Medical Laboratory Sciences, Department of Clinical Chemistry, The National Ribat University, Khartoum, Sudan.
Research Article
International Journal of Biological and Pharmaceutical Sciences Archive, 2022, 04(02), 013–024.
Article DOI: 10.53771/ijbpsa.2022.4.2.0081
Publication history:
Received on 04 August 2022; revised on 10 October 2022; accepted on 13 October 2022
Abstract:
Background: Atorvastatin is a lipid-lowering medication that causes skeletal muscle side effects by altering serum levels of skeletal muscle biomarkers. The aim of this study is to assess the effect of atorvastatin on muscle function and biomarker serum levels of CK, LDH, AST, Myoglobin, and Troponin I in Sudanese patients.
Method: The total study group of hindered participants, including 60 case group (under Atorvastatin treatment) and 40 healthy as a control group, was matched with age and sex for the case group. The serum CK, LDH, myoglobin, and lipid profiles in the study groups were estimated by automated chemistry analyzers in this study.
Result: Muscle pain was reported in case studies (55 = 91%). There was a significant increase in CK, LDH, and myoglobin among case studies when compared to the control group. The dose of drug showed no significant difference among the studied parameters. No correlation was found between CK and LDH with the duration of drug administration.
Conclusion: Atorvastatin medication causes skeletal muscle pain among case study and increase muscle biomarkers such as CK, LDH, and myoglobin levels.
Keywords:
Atorvastatin; Muscle pain; Ck; LDH; ALT; Myoglobin; Troponin I
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0